Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of GT300 in Healthy Subjects
NCT04963855Phase 1Unknown
- Sponsor
- Generian Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in Lewy body dementia (LBD) comparing GT300 with Placebo (2 arms). Primary endpoint: Pharmacokinetic at 8 days. Status: unknown.
02
Drugs
GT300
03
Conditions
Lewy body dementia (LBD)
Beyond the preview
Go deeper on NCT04963855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04963855.